Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment

Am J Hematol. 2004 Jul;76(3):283-5. doi: 10.1002/ajh.20112.


Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation. This complication has not previously been reported during treatment with sargramostim, a hematopoietic cytokine with activity that overlaps filgrastim. We report a case of Sweet's syndrome in association with sargramostim treatment following chemotherapy for acute myelogenous leukemia. A suspected second episode occurred after subsequent chemotherapy and sargramostim treatment. Physicians should be aware of this possible association because the signs and symptoms of Sweet's syndrome are easily mistaken as being due to infection.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Biopsy
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
  • Granulocyte-Macrophage Colony-Stimulating Factor / adverse effects*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Prednisone / therapeutic use
  • Recombinant Proteins
  • Remission Induction
  • Skin / pathology
  • Sweet Syndrome / chemically induced*
  • Sweet Syndrome / drug therapy
  • Sweet Syndrome / pathology


  • Recombinant Proteins
  • Cytarabine
  • sargramostim
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Prednisone
  • Daunorubicin